These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 39386278)
21. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants. Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978 [TBL] [Abstract][Full Text] [Related]
23. A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system. Costacurta F; Dodaro A; Bante D; Schöppe H; Peng JY; Sprenger B; He X; Moghadasi SA; Egger LM; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Dunzendorfer-Matt T; Naschberger A; Wang D; Kaserer T; Moro S; von Laer D; Heilmann E PLoS Pathog; 2024 Sep; 20(9):e1012522. PubMed ID: 39259728 [TBL] [Abstract][Full Text] [Related]
24. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission. Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509 [TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795 [TBL] [Abstract][Full Text] [Related]
26. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504 [No Abstract] [Full Text] [Related]
27. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. Tan B; Joyce R; Tan H; Hu Y; Wang J Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial. Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813 [TBL] [Abstract][Full Text] [Related]
29. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342 [TBL] [Abstract][Full Text] [Related]
30. Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study. Kim DH; Yoo MG; Kim NY; Choi SY; Jang M; An M; Jeong SJ; Kim J Osong Public Health Res Perspect; 2024 Apr; 15(2):137-149. PubMed ID: 38621766 [TBL] [Abstract][Full Text] [Related]
31. Highly specific SARS-CoV-2 main protease (M Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E Antiviral Res; 2024 Nov; 231():105969. PubMed ID: 39053514 [TBL] [Abstract][Full Text] [Related]
32. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J bioRxiv; 2022 Sep; ():. PubMed ID: 36119652 [TBL] [Abstract][Full Text] [Related]
33. Targeting the omicron variant of SARS-CoV-2 with phytochemicals from Saudi medicinal plants: molecular docking combined with molecular dynamics investigations. Eltaib L; Alzain AA J Biomol Struct Dyn; 2023 Nov; 41(19):9732-9744. PubMed ID: 36369836 [TBL] [Abstract][Full Text] [Related]
34. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations. Ou J; Lewandowski EM; Hu Y; Lipinski AA; Aljasser A; Colon-Ascanio M; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais PR; Tan H; Wang J; Chen Y; Choy JS PLoS Pathog; 2023 Aug; 19(8):e1011592. PubMed ID: 37651467 [TBL] [Abstract][Full Text] [Related]
35. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225 [TBL] [Abstract][Full Text] [Related]
36. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19. Bege M; Borbás A Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399271 [TBL] [Abstract][Full Text] [Related]
37. Structural and virologic mechanism of the emergence of resistance to M Hattori SI; Bulut H; Hayashi H; Kishimoto N; Takamune N; Hasegawa K; Furusawa Y; Yamayoshi S; Murayama K; Tamamura H; Li M; Wlodawer A; Kawaoka Y; Misumi S; Mitsuya H Proc Natl Acad Sci U S A; 2024 Sep; 121(37):e2404175121. PubMed ID: 39236245 [TBL] [Abstract][Full Text] [Related]
38. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790 [TBL] [Abstract][Full Text] [Related]
39. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J ACS Cent Sci; 2023 Aug; 9(8):1658-1669. PubMed ID: 37637734 [TBL] [Abstract][Full Text] [Related]
40. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]